FDA halts ABL Bio’s cancer drug, demands new trial after weak survival data
The FDA has told ABL Bio and Compass Therapeutics to run another trial for tovecimig after disappointing survival results, putting approval and royalty plans on hold.
Compass Therapeutics 1 article
The company-level identity of Compass Therapeutics is defined by bispecific antibody oncology, with dual angiogenesis pathway blockade showing how binding specificity is translated into a therapeutic mechanism. The company links tumor vascular biology targeting with biliary tract cancer therapeutics; solid tumor antiangiogenic therapy shows how antibody format or binding architecture is translated into a biological effect. For Compass Therapeutics, individual protein products remain separate tags, while tumor endothelial signaling modulation adds context to the broader biologics profile.